News

MoonLake Immunotherapeutics Investors Urged to Take Action Now

MoonLake Immunotherapeutics Investors Urged to Take Action Now

Important Notice for MoonLake Immunotherapeutics Shareholders

In light of recent developments, all shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) are strongly advised to be aware of a significant securities fraud class action lawsuit. This legal action has been initiated against the company, and it involves allegations of misrepresentations related to the company's leading drug candidate, sonelokimab (SLK).

What Should Investors Know?

MoonLake Immunotherapeutics, commonly referred to as MoonLake, has become a focal point of legal scrutiny due to claims that the company, along with some of its senior executives, made misleading statements about the efficacy of its drug in comparison to other monoclonal antibody treatments.

Details of the Lawsuit

The lawsuit, filed in the Southern District of New York, targets those who acquired shares of MoonLake within a specified time frame, from March 10, 2024, through September 29, 2025. The allegations highlight potential violations under the Securities Exchange Act of 1934, emphasizing the impact these misleading claims could have on investors' financial health.

Eligibility for Participation

Investors who purchased shares during this time period and believe they may have suffered losses are encouraged to review their options for joining this legal action. Importantly, involvement in this class action isn’t mandatory for recovering potential damages.

Deadline for Filing Claims

Individuals wishing to act as lead plaintiffs must file their paperwork by December 15, 2025. Being a lead plaintiff means taking on the responsibility of representing the entire class, but it isn’t a prerequisite for receiving any financial recovery.

Your Rights as a Shareholder

All legal representation related to this case will be handled on a contingency fee basis, ensuring that shareholders incur no upfront costs. This means that you won’t pay any fees unless a successful outcome is achieved in court.

Call to Action for Investors

If you believe that your investment in MoonLake Immunotherapeutics was affected by the alleged misrepresentations, it’s crucial to stay informed and proactive about your rights. Numerous resources are available to you for gaining a better understanding of the ongoing situation and for receiving assistance with any claims you may wish to file.

The Role of Bernstein Liebhard LLP

Bernstein Liebhard LLP, a reputable law firm that specializes in investor rights, is leading the charge in representing shareholders affected by this situation. With a strong track record of securing over $3.5 billion for its clients, this firm has extensive experience in navigating securities class actions. They have represented individual investors as well as larger institutional funds, reflecting their commitment to safeguarding the interests of all their clients.

Contact Information

For any individuals who wish to learn more or discuss their potential involvement in this class action lawsuit, please reach out to Investor Relations Manager Peter Allocco at (212) 951-2030 or via email at pallocco@bernlieb.com. You may also visit the official website for additional information and resources.

Frequently Asked Questions

What is the class action lawsuit against MoonLake Immunotherapeutics about?

The lawsuit alleges that MoonLake and certain executives made false statements regarding the effectiveness of their drug candidate, sonelokimab.

Who is eligible to join this class action?

Investors who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, are eligible to join.

What is the deadline for filing claims?

The deadline to file as a lead plaintiff is December 15, 2025.

Will I have to pay fees to join the lawsuit?

No, representation is on a contingency fee basis, meaning you only pay if the case is successful.

How can I contact someone for more information?

You can contact Peter Allocco at (212) 951-2030 or email him at pallocco@bernlieb.com for more details.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 4

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 3

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 9

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 3

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 4

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 5

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 4

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading

Top 5 Most Recently Viewed Articles

Toll Brothers' Q3 Results Show Steady Growth Amid Challenges

Updated Category News Views 160

Overview of Toll Brothers' Q3 Financial Performance On August 19, 2025, Toll Brothers, Inc. (NYSE: TOL), a prominent builder of luxury homes, reported robust financial results for its fiscal year 2025 third quarter, reflecting resilience in the luxury housing market. The results, concluding on July 31, 2025, demonstrate the company's adaptability in navigating current...

Continue Reading
SolarBank Revises Financial Statements for Transparency

Updated Category News Views 245

SolarBank Corporation Updates Financial Disclosures SolarBank Corporation (NASDAQ: SUUN) has recently announced an important update regarding its financial disclosures. The company has refiled its Audited Consolidated Annual Financial Statements for the fiscal year ending June 30, 2024. This refiled documentation was originally submitted on September 30, 2024, and...

Continue Reading
Coldwell Banker Warburg's Exciting Expansion to Brooklyn

Updated Category News Views 195

Coldwell Banker Warburg Expands to Brooklyn New DUMBO-based office marks the brokerage's first brick-and-mortar location in the fast-growing borough Coldwell Banker Warburg (CBW) is thrilled to announce a significant milestone in its expansion journey with the opening of its first office in Brooklyn. The new location, nestled in the vibrant DUMBO neighborhood, showcases...

Continue Reading
How REALTORS® Leverage AI and Tech to Transform Services

Updated Category News Views 187

Understanding the Embrace of AI and Technology by REALTORS® In recent times, the real estate industry has witnessed a remarkable transformation driven by the integration of technology, especially artificial intelligence. REALTORS® have been quick to adapt to these advancements, utilizing digital tools to enhance the services they provide to their clients. The insights...

Continue Reading
Anticipating Regal Rexnord's Earnings: What Investors Should Know

Updated Category News Views 129

Regal Rexnord's Upcoming Earnings Report Regal Rexnord (NYSE: RRX) is set to share its quarterly earnings report soon, igniting significant interest among investors. The anticipation surrounding this report stems from a combination of previous performance and market expectations that suggest growth and optimism. Expectations on Earnings Per Share Analysts have projected...

Continue Reading